# PeptideScanner evidence objects: Larazotide

Every published version of the records placed with Larazotide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/larazotide.json. Selected public evidence only; not medical advice.

- Objects: 13
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00362856-larazotide-v1"></a>

## ClinicalTrials.gov record NCT00362856

> PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct00362856-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00362856-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00362856-larazotide-v1
- Content SHA-256: `29aaef4a4f5950051ba815a5598490e89d9202590fe6dea3f34c66803157e826`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00362856 ([`ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b`](#source-ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b`](#source-ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b`](#source-ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b`](#source-ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b))

### Sources

<a id="source-ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b"></a>
- **ClinicalTrials.gov record NCT00362856 · retained source version 2017-09-12:4f5be39cdc6bc8497fbc568ebf9490ea4423961fd1d52358c2b0d7549413ce5b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00362856) (`ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00362856." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00362856-larazotide-v1 SHA-256: 29aaef4a4f5950051ba815a5598490e89d9202590fe6dea3f34c66803157e826.

---

<a id="clinicaltrials-gov-nct00386165-larazotide-v1"></a>

## ClinicalTrials.gov record NCT00386165

> PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct00386165-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00386165-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00386165-larazotide-v1
- Content SHA-256: `ba3846e013b3bbb7312a40eceaf9daef3139455181a6afcdebf93c5626e88b79`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00386165 ([`ctg-observation-nct00386165-2017-09-11-bb452dcac18a`](#source-ctg-observation-nct00386165-2017-09-11-bb452dcac18a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00386165-2017-09-11-bb452dcac18a`](#source-ctg-observation-nct00386165-2017-09-11-bb452dcac18a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00386165-2017-09-11-bb452dcac18a`](#source-ctg-observation-nct00386165-2017-09-11-bb452dcac18a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00386165-2017-09-11-bb452dcac18a`](#source-ctg-observation-nct00386165-2017-09-11-bb452dcac18a))

### Sources

<a id="source-ctg-observation-nct00386165-2017-09-11-bb452dcac18a"></a>
- **ClinicalTrials.gov record NCT00386165 · retained source version 2017-09-11:bb452dcac18a730567450a38143edeeb8f55b47889222f7459f0d824575171e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00386165) (`ctg-observation-nct00386165-2017-09-11-bb452dcac18a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00386165." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00386165-larazotide-v1 SHA-256: ba3846e013b3bbb7312a40eceaf9daef3139455181a6afcdebf93c5626e88b79.

---

<a id="clinicaltrials-gov-nct00386490-larazotide-v1"></a>

## ClinicalTrials.gov record NCT00386490

> PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct00386490-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00386490-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00386490-larazotide-v1
- Content SHA-256: `8e2461069125725ea28ed43c5fa50378bc505f956a543f7a679491d82aba0fee`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00386490 ([`ctg-observation-nct00386490-2017-09-12-41cd4de1f25f`](#source-ctg-observation-nct00386490-2017-09-12-41cd4de1f25f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00386490-2017-09-12-41cd4de1f25f`](#source-ctg-observation-nct00386490-2017-09-12-41cd4de1f25f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00386490-2017-09-12-41cd4de1f25f`](#source-ctg-observation-nct00386490-2017-09-12-41cd4de1f25f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00386490-2017-09-12-41cd4de1f25f`](#source-ctg-observation-nct00386490-2017-09-12-41cd4de1f25f))

### Sources

<a id="source-ctg-observation-nct00386490-2017-09-12-41cd4de1f25f"></a>
- **ClinicalTrials.gov record NCT00386490 · retained source version 2017-09-12:41cd4de1f25fd9d9515a95afc2bfb1f8196a6999b77cf32c57c9cd1a036e4ca3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00386490) (`ctg-observation-nct00386490-2017-09-12-41cd4de1f25f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00386490." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00386490-larazotide-v1 SHA-256: 8e2461069125725ea28ed43c5fa50378bc505f956a543f7a679491d82aba0fee.

---

<a id="clinicaltrials-gov-nct00492960-larazotide-v1"></a>

## ClinicalTrials.gov record NCT00492960

> PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct00492960-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00492960-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00492960-larazotide-v1
- Content SHA-256: `20fb1e4fc5ce9c8574a2ac661faceb323725541786a2a8fac1d6d8400554e50a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00492960 ([`ctg-observation-nct00492960-2017-09-20-f2928564c524`](#source-ctg-observation-nct00492960-2017-09-20-f2928564c524))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00492960-2017-09-20-f2928564c524`](#source-ctg-observation-nct00492960-2017-09-20-f2928564c524))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00492960-2017-09-20-f2928564c524`](#source-ctg-observation-nct00492960-2017-09-20-f2928564c524))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00492960-2017-09-20-f2928564c524`](#source-ctg-observation-nct00492960-2017-09-20-f2928564c524))

### Sources

<a id="source-ctg-observation-nct00492960-2017-09-20-f2928564c524"></a>
- **ClinicalTrials.gov record NCT00492960 · retained source version 2017-09-20:f2928564c524e7cc284363fe1f4567aa0996dc9d585a94409fe73d1420ea39b5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00492960) (`ctg-observation-nct00492960-2017-09-20-f2928564c524`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00492960." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00492960-larazotide-v1 SHA-256: 20fb1e4fc5ce9c8574a2ac661faceb323725541786a2a8fac1d6d8400554e50a.

---

<a id="clinicaltrials-gov-nct00620451-larazotide-v1"></a>

## ClinicalTrials.gov record NCT00620451

> PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct00620451-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00620451-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00620451-larazotide-v1
- Content SHA-256: `fdab1772868811e9d0010fc5594b4350097731cf354935db2a22c68b5766bd1f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00620451 ([`ctg-observation-nct00620451-2017-09-20-81258e10c690`](#source-ctg-observation-nct00620451-2017-09-20-81258e10c690))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00620451-2017-09-20-81258e10c690`](#source-ctg-observation-nct00620451-2017-09-20-81258e10c690))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00620451-2017-09-20-81258e10c690`](#source-ctg-observation-nct00620451-2017-09-20-81258e10c690))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00620451-2017-09-20-81258e10c690`](#source-ctg-observation-nct00620451-2017-09-20-81258e10c690))

### Sources

<a id="source-ctg-observation-nct00620451-2017-09-20-81258e10c690"></a>
- **ClinicalTrials.gov record NCT00620451 · retained source version 2017-09-20:81258e10c6900bec7cfae8f5433436c4a9b434acb10d82bdb5e72980f777a314** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00620451) (`ctg-observation-nct00620451-2017-09-20-81258e10c690`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00620451." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00620451-larazotide-v1 SHA-256: fdab1772868811e9d0010fc5594b4350097731cf354935db2a22c68b5766bd1f.

---

<a id="clinicaltrials-gov-nct00889473-larazotide-v1"></a>

## ClinicalTrials.gov record NCT00889473

> PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct00889473-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00889473-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00889473-larazotide-v1
- Content SHA-256: `6097f59d372502b0586e3cd4b3fb066297f3216901134ef52e02a234856639f2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00889473 ([`ctg-observation-nct00889473-2017-09-20-a07ae78224ec`](#source-ctg-observation-nct00889473-2017-09-20-a07ae78224ec))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00889473-2017-09-20-a07ae78224ec`](#source-ctg-observation-nct00889473-2017-09-20-a07ae78224ec))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct00889473-2017-09-20-a07ae78224ec`](#source-ctg-observation-nct00889473-2017-09-20-a07ae78224ec))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00889473-2017-09-20-a07ae78224ec`](#source-ctg-observation-nct00889473-2017-09-20-a07ae78224ec))

### Sources

<a id="source-ctg-observation-nct00889473-2017-09-20-a07ae78224ec"></a>
- **ClinicalTrials.gov record NCT00889473 · retained source version 2017-09-20:a07ae78224ec0b3e8fc59e3fc68e2233c3df35626779ffa3ab87425dffa0ad6b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00889473) (`ctg-observation-nct00889473-2017-09-20-a07ae78224ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00889473." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00889473-larazotide-v1 SHA-256: 6097f59d372502b0586e3cd4b3fb066297f3216901134ef52e02a234856639f2.

---

<a id="clinicaltrials-gov-nct01396213-larazotide-v1"></a>

## ClinicalTrials.gov record NCT01396213

> PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct01396213-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01396213-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct01396213-larazotide-v1
- Content SHA-256: `30da5251474f764276d4052bfcd755ecab7312671aac8836c23acf887818c802`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01396213 ([`ctg-observation-nct01396213-2017-09-20-7ba139d36870`](#source-ctg-observation-nct01396213-2017-09-20-7ba139d36870))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct01396213-2017-09-20-7ba139d36870`](#source-ctg-observation-nct01396213-2017-09-20-7ba139d36870))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct01396213-2017-09-20-7ba139d36870`](#source-ctg-observation-nct01396213-2017-09-20-7ba139d36870))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01396213-2017-09-20-7ba139d36870`](#source-ctg-observation-nct01396213-2017-09-20-7ba139d36870))

### Sources

<a id="source-ctg-observation-nct01396213-2017-09-20-7ba139d36870"></a>
- **ClinicalTrials.gov record NCT01396213 · retained source version 2017-09-20:7ba139d368702adc6d5b6390c4289e5cdbb7334b55fc7b5bd52909395c9e72f8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01396213) (`ctg-observation-nct01396213-2017-09-20-7ba139d36870`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01396213." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct01396213-larazotide-v1 SHA-256: 30da5251474f764276d4052bfcd755ecab7312671aac8836c23acf887818c802.

---

<a id="clinicaltrials-gov-nct05747534-larazotide-v1"></a>

## ClinicalTrials.gov record NCT05747534

> PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide.

- Evidence object: `story:clinicaltrials-gov-nct05747534-larazotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05747534-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct05747534-larazotide-v1
- Content SHA-256: `587f9cf0f950bac72e1cf531227c541865463c166cac3585afc864d51253ee54`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05747534 ([`ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47`](#source-ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47`](#source-ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide. ([`ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47`](#source-ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47`](#source-ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47))

### Sources

<a id="source-ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47"></a>
- **ClinicalTrials.gov record NCT05747534 · retained source version 2026-08-18:2f77ae5d1d478910bbbe486307fa9ba66477f1edf63b0947b6ab06b6618fadda** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05747534) (`ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05747534." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct05747534-larazotide-v1 SHA-256: 587f9cf0f950bac72e1cf531227c541865463c166cac3585afc864d51253ee54.

---

<a id="pubmed-pmid-23336683-larazotide-v1"></a>

## Commentary: larazotide acetate - an exciting new development for coeliac patients?

> PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23336683-larazotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23336683-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-23336683-larazotide-v1
- Content SHA-256: `cf07ff0916a1cd9f244ec738ca20b7647a1ea16d9dfebf2db7eafa3fa30c54cb`

### Claims and source pins

#### Headline

Commentary: larazotide acetate - an exciting new development for coeliac patients? ([`pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db`](#source-pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db))

#### Summary

PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db`](#source-pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db))

#### Paragraph 1

PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db`](#source-pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db`](#source-pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db))

### Sources

<a id="source-pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db"></a>
- **Commentary: larazotide acetate - an exciting new development for coeliac patients? · retained source version 1:2018-12-02:current:064af4bba5db73da94a54b459fb12f0686fd6f6d939cfa42474a2ea3213ea29c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23336683/) (`pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Commentary: larazotide acetate - an exciting new development for coeliac patients?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-23336683-larazotide-v1 SHA-256: cf07ff0916a1cd9f244ec738ca20b7647a1ea16d9dfebf2db7eafa3fa30c54cb.

---

<a id="pubmed-pmid-23336684-larazotide-v1"></a>

## Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply.

> PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23336684-larazotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23336684-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-23336684-larazotide-v1
- Content SHA-256: `3652bad4b6cee104c53b898200c55bf3c970bfac7be5f1def688b72d56cdb330`

### Claims and source pins

#### Headline

Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply. ([`pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e`](#source-pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e))

#### Summary

PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e`](#source-pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e))

#### Paragraph 1

PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e`](#source-pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e`](#source-pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e))

### Sources

<a id="source-pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e"></a>
- **Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply. · retained source version 1:2018-12-02:current:38df01b65a5e9d5c13b4033b2078b9dc69a1eab54cd0af8082c74bf25b481e5f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23336684/) (`pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-23336684-larazotide-v1 SHA-256: 3652bad4b6cee104c53b898200c55bf3c970bfac7be5f1def688b72d56cdb330.

---

<a id="pubmed-pmid-26983338-larazotide-v1"></a>

## \[Larazotide as an option in case of failure of a gluten-free diet\].

> PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26983338-larazotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-08-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26983338-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-26983338-larazotide-v1
- Content SHA-256: `cc0cd5ca6733e659aceb7d86076658a32224a6b9915dc6455cbcbb20fe22017a`

### Claims and source pins

#### Headline

\[Larazotide as an option in case of failure of a gluten-free diet\]. ([`pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae`](#source-pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae))

#### Summary

PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae`](#source-pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae))

#### Paragraph 1

PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae`](#source-pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae`](#source-pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae))

### Sources

<a id="source-pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae"></a>
- **\[Larazotide as an option in case of failure of a gluten-free diet\]. · retained source version 1:2021-08-27:current:1b51f8c755ae38112bf43dd63cf537268b80e3354f1473c66a7484d524a6e5da** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26983338/) (`pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Larazotide as an option in case of failure of a gluten-free diet\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-26983338-larazotide-v1 SHA-256: cc0cd5ca6733e659aceb7d86076658a32224a6b9915dc6455cbcbb20fe22017a.

---

<a id="pubmed-pmid-35211683-larazotide-v1"></a>

## Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.

> PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35211683-larazotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35211683-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-35211683-larazotide-v1
- Content SHA-256: `cb28c8f66fefb83e4a44fe32fb4d88c4dcb4b7f8368e7b9ec1a279f01e7731dc`

### Claims and source pins

#### Headline

Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. ([`pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e`](#source-pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e))

#### Summary

PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e`](#source-pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e))

#### Paragraph 1

PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e`](#source-pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e`](#source-pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e))

### Sources

<a id="source-pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e"></a>
- **Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. · retained source version 1:2022-03-17:current:21a6d571e71eae1c622448a401f96a2443ad7a49f57ddafb38ed37cb94295a3d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35211683/) (`pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-35211683-larazotide-v1 SHA-256: cb28c8f66fefb83e4a44fe32fb4d88c4dcb4b7f8368e7b9ec1a279f01e7731dc.

---

<a id="pubmed-pmid-40737433-larazotide-v1"></a>

## Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.

> PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40737433-larazotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40737433-larazotide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-40737433-larazotide-v1
- Content SHA-256: `2580a8aee1c2c359f7232d54ea09f26c79c7d9cfe6bdca9f28b5d87941e939c4`

### Claims and source pins

#### Headline

Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. ([`pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4`](#source-pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4))

#### Summary

PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4`](#source-pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4))

#### Paragraph 1

PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4`](#source-pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4`](#source-pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4))

### Sources

<a id="source-pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4"></a>
- **Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. · retained source version 1:2026-08-12:current:2bfb38e8b3d404ff0f81915c74aedaa11a7167350cf30b41c6ecdf8ac7c1e482** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40737433/) (`pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-40737433-larazotide-v1 SHA-256: 2580a8aee1c2c359f7232d54ea09f26c79c7d9cfe6bdca9f28b5d87941e939c4.

